If you’re looking for corporate venture capital in healthcare, take heart: the number of these deals hit a five-quarter high in Q2, up almost 40 percent from Q1, according to a report from CB Insights. Princeton, N.J.-based Opthotech, which develops products to help patients with age-related macular degeneration, got the biggest stack of CVC healthcare cash in Q2 deal: $50 million.
It’s this kind of key investment that allowed states like N.J. and Ohio to make respectable dents in CVC in Q2, but Massachusetts and Cali still accounted for more than half of CVC deals made and dollars earned in healthcare.
Series A funding also (finally) got a nod, earning 17 percent of total CVC investments in healthcare (up from 3 percent last quarter). But that money had to come from somewhere; Series B funding dropped from 34 percent in Q1 to only 14 percent. (And if you’re looking for seed funding from corporate venture capital, don’t hold your breath. There is nada.)
